Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources

Sandro Eridani, Umberto Mazza, Paolo Massaro, Maria Luisa La Targia, Anna Teresa Maiolo, Andrea Mosca

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Human pluripotential stem cells (PSC) are currently the target for transplantation attempts and genetic manipulation. We have therefore investigated the frequency and the expansion potential of PSC's in different types of blood samples. CD 34+ cells were thus obtained from human bone marrow (BM), as well as from peripheral blood (PB) and cord blood (CB) samples. After immuno-magnetic separation the highest yields of CD 34+ cells were from BM (1.08-2.25%) and CB (0.42-1.32%) while PB samples gave much lower values. Suspension cultures of PSC's from the three sources were then set up, in the presence of combinations of haemopoietic growth factors. A remarkable amplification of the nucleated cell pool was observed reaching a maximum between 10 and 15 days of culture; earliest and maximum expansion (up to 220-fold) was achieved when Erythropoietin (Epo) was added to the culture medium, but this resulted in reduction of colony-forming cells and differentiation into erythroid progenitors. Clonogenic tests for BFU-E's derived colonies showed a peak value at 5 days of liquid culture. Further studies are advisable to establish the best cytokine combination for a valuable ex vivo expansion, coupled with preservation of stem cell properties.

Original languageEnglish
Pages (from-to)295-298
Number of pages4
JournalBiotherapy
Volume10
Issue number4
Publication statusPublished - 1998

Fingerprint

Stem Cells
Cytokines
Fetal Blood
Erythropoietin
Bone Marrow Cells
Culture Media
Cell Differentiation
Intercellular Signaling Peptides and Proteins
Suspensions
Transplantation
Bone Marrow

Keywords

  • Bone marrow
  • Cord blood
  • Ex vivo expansion
  • Haemopoietic stem cells
  • Peripheral blood

ASJC Scopus subject areas

  • Pharmacology

Cite this

Eridani, S., Mazza, U., Massaro, P., Targia, M. L. L., Maiolo, A. T., & Mosca, A. (1998). Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources. Biotherapy, 10(4), 295-298.

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources. / Eridani, Sandro; Mazza, Umberto; Massaro, Paolo; Targia, Maria Luisa La; Maiolo, Anna Teresa; Mosca, Andrea.

In: Biotherapy, Vol. 10, No. 4, 1998, p. 295-298.

Research output: Contribution to journalArticle

Eridani, S, Mazza, U, Massaro, P, Targia, MLL, Maiolo, AT & Mosca, A 1998, 'Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources', Biotherapy, vol. 10, no. 4, pp. 295-298.
Eridani S, Mazza U, Massaro P, Targia MLL, Maiolo AT, Mosca A. Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources. Biotherapy. 1998;10(4):295-298.
Eridani, Sandro ; Mazza, Umberto ; Massaro, Paolo ; Targia, Maria Luisa La ; Maiolo, Anna Teresa ; Mosca, Andrea. / Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources. In: Biotherapy. 1998 ; Vol. 10, No. 4. pp. 295-298.
@article{f9b6fd232f304f37b51f7cf62028306e,
title = "Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources",
abstract = "Human pluripotential stem cells (PSC) are currently the target for transplantation attempts and genetic manipulation. We have therefore investigated the frequency and the expansion potential of PSC's in different types of blood samples. CD 34+ cells were thus obtained from human bone marrow (BM), as well as from peripheral blood (PB) and cord blood (CB) samples. After immuno-magnetic separation the highest yields of CD 34+ cells were from BM (1.08-2.25{\%}) and CB (0.42-1.32{\%}) while PB samples gave much lower values. Suspension cultures of PSC's from the three sources were then set up, in the presence of combinations of haemopoietic growth factors. A remarkable amplification of the nucleated cell pool was observed reaching a maximum between 10 and 15 days of culture; earliest and maximum expansion (up to 220-fold) was achieved when Erythropoietin (Epo) was added to the culture medium, but this resulted in reduction of colony-forming cells and differentiation into erythroid progenitors. Clonogenic tests for BFU-E's derived colonies showed a peak value at 5 days of liquid culture. Further studies are advisable to establish the best cytokine combination for a valuable ex vivo expansion, coupled with preservation of stem cell properties.",
keywords = "Bone marrow, Cord blood, Ex vivo expansion, Haemopoietic stem cells, Peripheral blood",
author = "Sandro Eridani and Umberto Mazza and Paolo Massaro and Targia, {Maria Luisa La} and Maiolo, {Anna Teresa} and Andrea Mosca",
year = "1998",
language = "English",
volume = "10",
pages = "295--298",
journal = "Biotherapy",
issn = "0921-299X",
publisher = "Springer International Publishing AG",
number = "4",

}

TY - JOUR

T1 - Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources

AU - Eridani, Sandro

AU - Mazza, Umberto

AU - Massaro, Paolo

AU - Targia, Maria Luisa La

AU - Maiolo, Anna Teresa

AU - Mosca, Andrea

PY - 1998

Y1 - 1998

N2 - Human pluripotential stem cells (PSC) are currently the target for transplantation attempts and genetic manipulation. We have therefore investigated the frequency and the expansion potential of PSC's in different types of blood samples. CD 34+ cells were thus obtained from human bone marrow (BM), as well as from peripheral blood (PB) and cord blood (CB) samples. After immuno-magnetic separation the highest yields of CD 34+ cells were from BM (1.08-2.25%) and CB (0.42-1.32%) while PB samples gave much lower values. Suspension cultures of PSC's from the three sources were then set up, in the presence of combinations of haemopoietic growth factors. A remarkable amplification of the nucleated cell pool was observed reaching a maximum between 10 and 15 days of culture; earliest and maximum expansion (up to 220-fold) was achieved when Erythropoietin (Epo) was added to the culture medium, but this resulted in reduction of colony-forming cells and differentiation into erythroid progenitors. Clonogenic tests for BFU-E's derived colonies showed a peak value at 5 days of liquid culture. Further studies are advisable to establish the best cytokine combination for a valuable ex vivo expansion, coupled with preservation of stem cell properties.

AB - Human pluripotential stem cells (PSC) are currently the target for transplantation attempts and genetic manipulation. We have therefore investigated the frequency and the expansion potential of PSC's in different types of blood samples. CD 34+ cells were thus obtained from human bone marrow (BM), as well as from peripheral blood (PB) and cord blood (CB) samples. After immuno-magnetic separation the highest yields of CD 34+ cells were from BM (1.08-2.25%) and CB (0.42-1.32%) while PB samples gave much lower values. Suspension cultures of PSC's from the three sources were then set up, in the presence of combinations of haemopoietic growth factors. A remarkable amplification of the nucleated cell pool was observed reaching a maximum between 10 and 15 days of culture; earliest and maximum expansion (up to 220-fold) was achieved when Erythropoietin (Epo) was added to the culture medium, but this resulted in reduction of colony-forming cells and differentiation into erythroid progenitors. Clonogenic tests for BFU-E's derived colonies showed a peak value at 5 days of liquid culture. Further studies are advisable to establish the best cytokine combination for a valuable ex vivo expansion, coupled with preservation of stem cell properties.

KW - Bone marrow

KW - Cord blood

KW - Ex vivo expansion

KW - Haemopoietic stem cells

KW - Peripheral blood

UR - http://www.scopus.com/inward/record.url?scp=0031897606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031897606&partnerID=8YFLogxK

M3 - Article

C2 - 9592017

AN - SCOPUS:0031897606

VL - 10

SP - 295

EP - 298

JO - Biotherapy

JF - Biotherapy

SN - 0921-299X

IS - 4

ER -